Other · developed by Ocular Therapeutix
OTX-TIC is an intracameral implant injected into the anterior chamber of the eye, also named OTX-TIC high dose Travoprost Intracameral Implant. It is studied in open-angle glaucoma and ocular hypertension.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05335122 | Phase 2 | Open Angle Glaucoma | Completed | OCUL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ocular HypertensionOpen Angle Glaucoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the OCUL page.
See OCUL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OCUL catalysts and pipeline →